VT02956 is a LATS inhibitor ( IC 50 : 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids.IC50& Target:IC50: 0.76 nM for LATS1, 0.52 nM for LATS2In Vitro:VT02956 (2 μM, 0-30 min) reduces YAP/TAZ phosphorylation in HEK293A cells and 4T1 cells. VT02956 (2 μM, 2 days) reduces ERα and its target genes TFF1 and GREB1 in breast tumor organoids BTO-02. VT02956 (2 μM, 4 days) inhibits the proliferation oBiological Activity:VT02956 is a LATS inhibitor ( IC 50 : 0.76u2009nM for LATS1, 0.52u2009nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids. Molecular Formula: C22H23N5O. Molecular Weight: 373.45.
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- V659222-5mg
- Product Size:
- 5mg
